News and Trends 10 Dec 2021 European Biotech Investors Cap Off Record Year in Fundraising The year 2021 is closing with a biotech investment rush as Eir Ventures, Apollo Health Ventures, and Merck’s venture capital arm M Ventures raise impressive funds to speed up life sciences innovation. This year is set to break records in terms of the money flowing into institutional life science investors. With 2021 not even finished, […] December 10, 2021 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2020 Medicxi to Shake up the Biotech VC Investment Model with €200M Fund UK-based investment firm Medicxi aims to attract more investors to the life sciences with a new fund that lets them cash in on their investments earlier than conventional funds. Last week, Medicxi closed a €200M fund called Medicxi Secondary 1 (MS1), which was co-led by the UK’s Pantheon and Switzerland’s LGT Capital Partners. The aim […] October 1, 2020 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
More News! 19 Jul 2019 UK VC Medicxi Closes Third Fund with €400M to Boost European Biotech The UK-based venture capital investment firm Medicxi has closed its third fund, totaling €400M, to nurture early- and late-stage healthcare biotech companies in Europe. The firm will begin investing in the first beneficiary companies of this fund in the next few months. The big round was raised in just six weeks, and dwarfs Medicxi’s previous […] July 19, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2019 Evotec Spinoff to Develop Cancer Drugs that Block DNA Repair Breakpoint Therapeutics, a spinoff from the German biotech Evotec, has raised €30M to develop drugs that block DNA repair mechanisms in drug-resistant cancers. Breakpoint Therapeutics aims to develop first-in-class drugs that kill cancer cells by sabotaging their DNA repair machinery. Having taken on a number of Evotec’s drug development programs, Breakpoint aims to have its […] July 8, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Dec 2017 Bored Between the Holidays? Watch these Biotech Videos! Christmas might have passed, but we have more videos for you to watch on a dreary winter day! Here are our highlights from 2017. It’s vacation time! If you’ve worn out the holiday movies, catch up on our biotech ones. It was a busy year, and we produced a lot, thanks to our new Hangouts […] December 28, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 2 Nov 2017 Meet the Top Biotech Investor Who Picked His Career By Accident Kevin Johnson, Partner at Medicxi, joined us last week for our Meetup in London. He told us how he ended as an investor despite starting in biotech. Fresh from his PhD at Cambridge, Johnson stepped into biotech and led the development of a number of human antibodies at Cambridge Antibody Technology (CAT). The company was eventually responsible for […] November 2, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 4 Sep 2017 Meet this Blockbuster Developer turned Partner at a Headlining VC Kevin Johnson told me the story and lessons of his career, from CTO of Cambridge Antibody Technology to General Partner at Medicxi. Since starting his biotech career as the lead developer of one of biotech’s biggest success stories, Humira, Kevin Johnson has continued in biotech as a force to be reckoned with. He joined the […] September 4, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2017 Why European Biotech Startups Should Attend American Conferences! We all know conferences are important. To be on the same page, let’s brainstorm the word. What comes to mind? A long list of associations – networking, partnering, businesses, meetings, new people, knowledge, presentations, talks, panels, companies. We could go on and on – one thing is clear: they are one of the most effective […] July 13, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2017 UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of famous Index Ventures went solo in 2016 and became Medicxi, the VC was able to raise a huge sum of €210M in its first round to support early-stage, single-asset […] June 15, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 7 Mar 2017 UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […] March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 9 Feb 2017 After its First Success, the Virtual Biotech Team is Back at it Again SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat […] February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Dec 2016 Discussing the Future of Personalized Medicine with Biotech Experts Personalized medicine has been a popular topic in the last few years, but when will it materialize? Experts discussed the current challenges at Labiotech Refresh. Jean-Pol Detiffe is the CEO of OncoDNA, a company using next-generation sequencing to match patients with a personalized cancer treatment. In his opinion, one of the main challenges in the […] December 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email